Epigenomics Receives Notice of FDA Pending Approval

Epigenomics Receives FDA Notification About Status of Pending Approval Decision for Epi proColon® Berlin, Germany, January 8, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the already submitted and available…

Read More

Curetis IPO

Curetis AG / Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million .  Holzgerlingen, Germany, November 10, 2015 — Curetis N.V.[1] (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announces the completion of its initial public offering, which was launched on October 28, 2015…

Read More

Epigenomics Update at AMP 2015 Annual Meeting

http://www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-ag-gibt-ein-update-ueber-bluttests-zur-krebsfrueherkennung-auf-der-jahrestagung-2015-der.html

Read More

2013 ICAAC Poster

GBC Attended the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado September 9 – 13, 2013 Click here for Poster PDF:  [wpdm_file id=8] Poster Title:  Evaluation of a Molecular Multiplex Test For Detection of Respiratory Microorganism and Antibiotic Resistance Genes in Clinical Specimens Authors:  M. Malczynski1, M. Klein2, N. Mucci3, K. Schwarzer2, A.…

Read More

Biopreservation and Biobanking Publication

Neil R. Mucci of GBC Leads caHUB Committee in Developing, Summarizing and Publishing Recommendations that Promote Availability of Biospecimens for Research SEATTLE, April 25, 2013 Global BioClinical (GBC) is pleased to announce the publication of an article in the April 2013 issue of Biopreservation and Biobanking titled:  Meeting Research Needs with Postmortem Biospecimen Donation:  Summary of Recommendations for…

Read More

GBC Supports Curetis AG Trial in U.S.

Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance December 6, 2012 – 10:44:28 – Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples (live-PR.com) – Holzgerlingen, Germany, December 6, 2012 — Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract)…

Read More

Global BioClinical Welcomes Jennifer Maas

Experienced Clinical Research Manager Joins Seattle-based Contract Consulting and Clinical Research Services Company SEATTLE, May 31, 2012 /PRNewswire-iReach/ — Global BioClinical (GBC) is pleased to announce the addition of Jennifer Maas to the corporate team. Ms. Maas has joined GBC as a Senior Consultant and Clinical Operations Manager.  Formerly a Clinical Research Manager at Epigenomics, Inc., Ms. Maas joins GBC…

Read More

Global BioClinical Launches New Website

New Site Describes Expertise-Based Clinical Research Services Including Consulting, Business, Trials, and Biospecimen Services SEATTLE, April 4, 2012 /PRNewswire-iReach/ — Global BioClinical (GBC) the Seattle-based contract consulting and clinical research services company has launched a new website at www.globalbioclinical.com. The site offers expanded information on the company, services offered, partner registration, new search capabilities, and links to common professional and social…

Read More